Clinical review report : indication: Doravirine (Pifeltro) is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to Doravirine. Doravirine (Pifeltro) (Merck Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Outcome assessment (Medical care).

Physical Description:

1 online resource (86 pages) : illustrations.

Edition:

Final (with redactions).

Place of Publication:

Ottawa (ON) : CADTH, 2019.

Summary:

The objective of this systematic review was to evaluate the beneficial and harmful effects of doravirine, in combination with other antiretroviral medicinal products, for the treatment of HIV-1 infection in adults without past or present evidence of viral resistance to Doravirine.

Contents:

Abbreviations

Executive Summary

Introduction

Results and Interpretation

Conclusions

Disease Prevalence and Incidence

Standards of Therapy

Drug

Objectives and Methods

Objectives

Methods

Results

Findings from the Literature

Included Studies

Exposure to Study Treatments

Critical Appraisal

Efficacy

Harms

Discussion

Summary of Available Evidence

Interpretation of Results

Appendix 1. Patient Input Summary

Appendix 2. Literature Search Strategy

Appendix 3. Excluded Studies

Appendix 4. Detailed Outcome Data

Appendix 5. Summary of Indirect Comparisons

References.

Notes:

Includes bibliographical references.

Description based on publisher supplied metadata and other sources.